Drugs / N-acetyl cysteine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT01896492 Comparator | Jan 2011 → Jun 2013 | polycystic ovary syndrome | Woman's Health University Hospital, Egypt | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | N-acetyl cysteine | “N-acetyl cysteine, as an antioxidant, has been suggested as an adjuvant in clomiphene-resistant cases” NCT01896492 ↗ |
| Known as | NAC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01896492 ↗ |
| Route | Oral | “in a dose of 1.2 g/d orally” NCT01896492 ↗ |